ReviewCurrent medicinal chemistry2016
Why Antidiabetic Vanadium Complexes are Not in the Pipeline of "Big Pharma" Drug Research? A Critical Review.
Review in Current medicinal chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Speciation, Protein Binding, Biotransformation, and Cytotoxicity of a VV-Lactate Complex.Inorganic chemistry · 2026Article
- Oxovanadium(iv/v) lawsone-based complexes: synthesis, characterization, DFT studies, and multifunctional biological activities.RSC advances · 2026Article
- Centrifuge-Less Mixed Micelle-Mediated Cloud Point Extraction-Spectrophotometric Determination of Vanadium Using 4-Nitrocatechol and Cetylpyridinium Chloride.International journal of molecular sciences · 2025Article
- In-Depth Mass Spectrometry Study of Vanadium(IV) Complexes with Model Peptides.Inorganic chemistry · 2024Article
- Experimental and Computational Studies on the Interaction of DNA with Hesperetin Schiff Base CuInternational journal of molecular sciences · 2024Article
- Vanadium Complexes with Thioanilide Derivatives of Amino Acids: Inhibition of Human Phosphatases and Specificity in Various Cell Models of Metabolic Disturbances.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Exploring the Biological Effects of Anti-Diabetic Vanadium Compounds in the Liver, Heart and Brain.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Vanadium Compounds with Antidiabetic Potential.International journal of molecular sciences · 2023Review
- Interaction of Vanadium Complexes with Proteins: Revisiting the Reported Structures in the Protein Data Bank (PDB) since 2015.Molecules (Basel, Switzerland) · 2023Review
- Review
- Current Insights on the Use of Insulin and the Potential Use of Insulin Mimetics in Targeting Insulin Signalling in Alzheimer's Disease.International journal of molecular sciences · 2022Review
- Toxicity of Nanocomplexes Containing Gadolinium Orthovanadate Nanoparticles and Cholesterol.Biological trace element research · 2022Article
- Vanadium(IV)-Chlorodipicolinate Protects against Hepatic Steatosis by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammation.Antioxidants (Basel, Switzerland) · 2022Article
- Biological Properties of Transition Metal Complexes with Metformin and Its Analogues.Pharmaceuticals (Basel, Switzerland) · 2022Review
- High doses of catecholamines activate glucose transport in human adipocytes independently from adrenoceptor stimulation or vanadium addition.World journal of diabetes · 2022Article
- Heteroleptic Oxidovanadium(V) Complexes with Activity against Infective and Non-Infective Stages ofMolecules (Basel, Switzerland) · 2021Article
- Synthesis, Characterization, and In Vitro Insulin-Mimetic Activity Evaluation of Valine Schiff Base Coordination Compounds of Oxidovanadium(V).Biomedicines · 2021Article
- Are vanadium complexes druggable against the main protease MInorganica chimica acta · 2021Article
- Vanadium-dependent activation of glucose transport in adipocytes by catecholamines is not mediatedWorld journal of diabetes · 2020Article
- The liposomal delivery of hydrophobic oxidovanadium complexes imparts highly effective cytotoxicity and differentiating capacity in neuroblastoma tumour cells.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Public academic research sites, private institutions as well as small companies have made substantial contributions to the ongoing development of antidiabetic vanadium compounds. But why is this endeavor not echoed by the globally operating pharmaceutical companies, also known as "Big Pharma"? Intriguingly, today's clinical practice is in great need to improve or replace insulin treatment against Diabetes Mellitus (DM). Insulin is the mainstay therapeutically and economically. So, why do those companies develop potential antidiabetic drug candidates without vanadium (vanadium- free)? We gathered information about physicochemical and pharmacological properties of known vanadium-containing antidiabetic compounds from the specialized literature, and converted the data into explanations (arguments, the "pros and cons") about the underpinnings of antidiabetic vanadium. Some discoveries were embedded in chronological order while seminal reviews of the last decade about the Medicinal chemistry of vanadium and its history were also listed for further understanding. In particular, the concepts of so-called "noncomplexed or free" vanadium species (i.e. inorganic oxido-coordinated species) and "biogenic speciation" of antidiabetic vanadium complexes were found critical and subsequently documented in more details to answer the question.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.